Neil Kumar, Chief Executive Officer at BridgeBio Pharma, Inc. (BBIO), sold 80,000 shares at $46.71 ($3.7M) on 2025-08-08, disclosed to the SEC on 2025-08-11.
Scheduled sale ($3.7M) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $45.09 | 6,784 | $306K | 8.3% |
| 2 | $45.09 | 6,784 | $306K | 8.3% |
| 3 | $45.64 | 13,216 | $603K | 16.4% |
| 4 | $45.64 | 13,216 | $603K | 16.4% |
| 5 | $45.88 | 11,795 | $541K | 14.8% |
| 6 | $45.88 | 11,795 |
| $541K |
| 14.8% |
| 7 | $46.71 | 8,205 | $383K | 10.5% |
| 8 | $46.71 | 8,205 | $383K | 10.5% |
| Total | $45.84 avg | 80,000 | $3.7M | 100% |
| Filing → |
| BBIO | SELL | 2026-06-08 | $4.6M | — | Filing → |
| BBIO | SELL | 2026-05-26 | $1.8M | — | Filing → |
| BBIO | SELL | 2026-05-11 | $5.3M | — | Filing → |